News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy
Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a
QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/PME-fähig) (Paris:ALVAL), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen
MD Medical Group Investments Plc: MD Medical Group announces intention to delist GDRs from the LSE
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences
Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to isaralgagene
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
NanoString to Host Conference Call on Monday, May 22, 2023, to Provide Comments on Decision of the Regional Court of Munich
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will host a conference call on
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents
Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
NanoString nimmt Stellung zur Entscheidung des Landgerichts München
NanoString Technologies, Inc. (Nasdaq: NSTG), ein führender Anbieter von biowissenschaftlichen Werkzeugen für die Forschung und die translationale Forschung, reagierte heute auf die jüngste
Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on July 26, 2023, to all shareholders of record as of the close of
NanoString Responds to Decision of the Regional Court of Munich
NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today responded to the Regional Court of Munich’s recent decision
Aurinia Announces 2023 Annual General Meeting Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced voting results for its annual general meeting (the “Meeting”) of shareholders held on May 17, 2023.